Slingshot Insights | Catalyst

Catalyst

Slingshot members are tracking this event:

PharmaMar (PHM.MC) Initiates Phase 1 Study Evaluating PM1183 (lurbinectedin) in Certain Types of Unresectable/Advanced Solid Tumors

Source Link:: https://www.pharmamar.com/wp-content/uploads/2016/11/PR_PharmaMar-begins-a-Phase-I-study-of-PM1183-in-Japan-for-the-treatment-of-solid-tumors.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Nov 28, 2016

Related Projects

A conversation with PharmaMar's Director of Oncology, Newly Hired COO, and Director of Capital Markets to discuss the upcoming pivotal year for the firm. PHM.MC, CLVS, TSRO Executed On: Mar 09, 2017 at 11:00 AM EST

Related Keywords Phase 1, Initiation, Pm1183, Lurbinectedin, Unresectable, Advanced, Solid Tumors